Positive new and updated data from a phase I and pivotal phase II trial (ELM-1 and ELM-2), evaluating investigational odronextamab in patients with relapsed/refractory diffuse large B-cell lymphoma, were presented in an oral session at the 64th American Society of Hematology Annual Meeting and Exposition and will form the basis of planned submissions to regulatory authorities in 2023, including to FDA.
Results from the RIGHT Choice phase II trial showed that Kisqali (ribociclib) plus endocrine therapy demonstrated a nearly one-year PFS benefit for patients with aggressive breast cancer.
Detailed results from the CAPItello-291 phase III trial showed AstraZeneca’s capivasertib in combination with Faslodex (fulvestrant) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo plus Faslodex in patients with hormone receptor-positive, human epidermal growth factor receptor 2-low or negative, locally advanced or metastatic breast cancer, following recurrence or progression on, or after, endocrine therapy (with or without a CDK4/6 inhibitor).
Retrospective analyses of data from the Suppression of Ovarian Function Trial trial, led by Hologic Inc. and its subsidiary, Biotheranostics Inc., showed that the Breast Cancer Index test identified which premenopausal patients with early-stage, hormone-receptor positive breast cancer benefited from the addition of ovarian function suppression to primary adjuvant endocrine therapy.
A study published today by researchers at Fox Chase Cancer Center suggests that independent of demographic factors like socioeconomic status and access to healthcare, race itself may predict disparate outcomes between patients.
In April 2022, FDA issued proposed product standards banning menthol flavoring in cigarettes and cigars; however, the benefits of these product standards could be weakened by the role of substitute products still available in the market.
In a study published in Science, UCSF researchers Kevin Lou, Luke Gilbert, and Kevan Shokat demonstrated the discovery of a cellular uptake pathway important for large and complex molecules, which bind in unconventional ways to their targets and are efficiently taken up by target cells.
Cancer Research UK, The University of Manchester, and Roche Products Ltd. opened a multi-drug, precision medicine trial for people with rare cancers who need more treatment options. The trial is set up to recruit both pediatric and adult patients with any rare cancer type.
Topline results from the pivotal phase III KEYNOTE-859 trial investigating Keytruda (pembrolizumab), in combination with chemotherapy for the first-line treatment of patients with human epidermal growth factor receptor 2 (HER2)-negative locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma, were positive.
Patients with high-risk stage III-IV melanoma who received Keytruda (pembrolizumab) after surgery reported a better quality of life than patients who received the previous standard-of-care treatment with either ipilimumab or high-dose interferon, according to a large clinical trial led by the SWOG Cancer Research Network.
